Accounts Receivable, after Allowance for Credit Loss, Current in USD of Lexaria Bioscience Corp. from Q3 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Lexaria Bioscience Corp. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q3 2010 to Q3 2025.
  • Lexaria Bioscience Corp. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Aug 2025 was $368K, a 138% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Lexaria Bioscience Corp. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $368K +$214K +138% 31 Aug 2025 10-K 28 Nov 2025
Q2 2025 $358K +$150K +71.8% 31 May 2025 10-Q 14 Jul 2025
Q1 2025 $331K -$25.9K -7.26% 28 Feb 2025 10-Q 14 Apr 2025
Q4 2024 $263K -$271K -50.7% 30 Nov 2024 10-Q 10 Jan 2025
Q3 2024 $154K +$27.8K +21.9% 31 Aug 2024 10-K 28 Nov 2025
Q2 2024 $208K +$36.2K +21% 31 May 2024 10-Q 12 Jul 2024
Q1 2024 $357K +$220K +161% 29 Feb 2024 10-Q 09 Apr 2024
Q4 2023 $535K +$248K +86.8% 30 Nov 2023 10-Q 12 Jan 2024
Q3 2023 $127K -$75.1K -37.2% 31 Aug 2023 10-K 26 Nov 2024
Q2 2023 $172K +$17.4K +11.2% 31 May 2023 10-Q 14 Jul 2023
Q1 2023 $137K -$370K -73% 28 Feb 2023 10-Q 14 Apr 2023
Q4 2022 $286K -$175K -38% 30 Nov 2022 10-Q/A 18 Jan 2023
Q3 2022 $202K -$141K -41.1% 31 Aug 2022 10-K 20 Nov 2023
Q2 2022 $155K -$799K -83.8% 31 May 2022 10-Q 14 Jul 2022
Q1 2022 $507K -$121K -19.3% 28 Feb 2022 10-Q 11 Apr 2022
Q4 2021 $462K +$34.2K +8% 30 Nov 2021 10-Q 14 Jan 2022
Q3 2021 $342K +$28.5K +9.07% 31 Aug 2021 10-K 28 Nov 2022
Q2 2021 $954K +$700K +276% 31 May 2021 10-Q 15 Jul 2021
Q1 2021 $628K +$401K +176% 28 Feb 2021 10-Q 14 Apr 2021
Q4 2020 $427K +$101K +31.1% 30 Nov 2020 10-Q 14 Jan 2021
Q3 2020 $314K +$40.8K +14.9% 31 Aug 2020 10-K 29 Nov 2021
Q2 2020 $254K +$28.1K +12.5% 31 May 2020 10-Q 29 Jun 2020
Q1 2020 $227K +$8.16K +3.73% 29 Feb 2020 10-Q 03 Apr 2020
Q4 2019 $326K +$111K +51.7% 30 Nov 2019 10-Q 09 Jan 2020
Q3 2019 $273K +$7.39K +2.78% 31 Aug 2019 10-K 15 Oct 2020
Q2 2019 $226K -$41.9K -15.7% 31 May 2019 10-Q 08 Jul 2019
Q1 2019 $219K +$30.8K +16.4% 28 Feb 2019 10-Q 15 Apr 2019
Q4 2018 $215K +$143K +199% 30 Nov 2018 10-Q 11 Jan 2019
Q3 2018 $266K +$220K +487% 31 Aug 2018 10-K 14 Nov 2019
Q2 2018 $268K +$210K +367% 31 May 2018 10-Q 13 Jul 2018
Q1 2018 $188K +$165K +697% 28 Feb 2018 10-Q 12 Apr 2018
Q4 2017 $71.9K -$577K -88.9% 30 Nov 2017 10-Q 12 Jan 2018
Q3 2017 $45.3K -$85.8K -65.4% 31 Aug 2017 10-K 14 Nov 2018
Q2 2017 $57.4K +$42.8K +294% 31 May 2017 10-Q 14 Jul 2017
Q1 2017 $23.6K -$20K -45.9% 28 Feb 2017 10-Q 14 Apr 2017
Q4 2016 $649K +$614K +1763% 30 Nov 2016 10-Q 13 Jan 2017
Q3 2016 $131K +$99.7K +318% 31 Aug 2016 10-K 27 Nov 2017
Q2 2016 $14.6K -$7.06K -32.7% 31 May 2016 10-Q 13 Jul 2016
Q1 2016 $43.7K +$8.64K +24.7% 29 Feb 2016 10-Q 13 Apr 2016
Q4 2015 $34.8K -$40.5K -53.8% 30 Nov 2015 10-Q 08 Jan 2016
Q3 2015 $31.4K -$65.6K -67.6% 31 Aug 2015 10-K 29 Nov 2016
Q2 2015 $21.6K -$77.1K -78.1% 31 May 2015 10-Q 14 Jul 2015
Q1 2015 $35K -$65.3K -65.1% 28 Feb 2015 10-Q 14 Apr 2015
Q4 2014 $75.3K -$55.3K -42.3% 30 Nov 2014 10-Q 14 Jan 2015
Q3 2014 $97K +$17.8K +22.5% 31 Aug 2014 10-K 27 Nov 2015
Q2 2014 $98.7K -$53.1K -35% 31 Jul 2014 10-Q 14 Nov 2014
Q1 2014 $100K -$66.9K -40% 30 Apr 2014 10-Q 12 Jun 2014
Q4 2013 $131K -$109K -45.5% 31 Jan 2014 10-Q 12 Mar 2014
Q3 2013 $79.2K -$212K -72.8% 31 Oct 2013 10-KT 09 Dec 2014
Q2 2013 $152K -$346K -69.5% 31 Jul 2013 10-Q 10 Sep 2013
Q1 2013 $167K +$27.7K +19.9% 30 Apr 2013 10-Q 12 Jun 2013
Q4 2012 $240K +$63.5K +36% 31 Jan 2013 10-Q 13 Mar 2013
Q3 2012 $291K +$60.1K +26% 31 Oct 2012 10-K 24 Jan 2014
Q2 2012 $498K +$266K +115% 31 Jul 2012 10-Q 12 Sep 2012
Q1 2012 $140K 30 Apr 2012 10-Q 07 Jun 2012
Q4 2011 $176K 31 Jan 2012 10-Q 13 Mar 2012
Q3 2011 $231K +$156K +208% 31 Oct 2011 10-K 29 Jan 2013
Q2 2011 $232K 31 Jul 2011 10-Q 14 Sep 2011
Q3 2010 $74.9K 31 Oct 2010 10-K 30 Jan 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.